Sec Form 13G Filing - Arie Belldegrun, M.D. @ Allogene Therapeutics, Inc.

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)*

Allogene Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

019770106

(CUSIP Number)

12/31/2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

019770106

Names of Reporting Persons

Arie Belldegrun, M.D.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,621,280.00
6	Shared Voting Power 8,772,287.00
7	Sole Dispositive Power 3,621,280.00
8	Shared Dispositive Power 8,772,287.00

Aggregate Amount Beneficially Owned by Each Reporting Person

12,393,567.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

5.8 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

019770106

Names of Reporting Persons

Bellco Legacy LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 539,867.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 539,867.00

Aggregate Amount Beneficially Owned by Each Reporting Person

539,867.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

0.3 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

019770106

Names of Reporting Persons

Bellco Legacy IV LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,710,120.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,710,120.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,710,120.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

2.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

019770106

Names of Reporting Persons

Vida Ventures LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,798,163.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,798,163.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,798,163.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

0.8 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

019770106

Names of Reporting Persons

Vida Ventures III, L.P.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,720,172.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,720,172.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,720,172.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

0.8 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

019770106

Names of Reporting Persons

Vida Ventures III-A, L.P.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,965.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,965.00

Aggregate Amount Beneficially Owned by Each Reporting Person

3,965.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

0.0 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Allogene Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

210 East Grand Avenue, South San Francisco, CA, 94080.

Item 2.

(a)

Name of person filing:

Arie BelldegrunBellco Legacy LLCBellco Legacy IV LLCVida Ventures LLCVida Ventures III, L.P.Vida Ventures III-A, L.P.

(b)

Address or principal business office or, if none, residence:

Arie Belldegrun: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067Bellco Legacy LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067Bellco Legacy IV LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067Vida Ventures LLC: 40 Broad Street, #201, Boston, MA 02109Vida Ventures III, L.P.: 40 Broad Street, #201, Boston, MA 02109Vida Ventures III-A, L.P.: 40 Broad Street, #201, Boston, MA 02109

(c)

Citizenship:

Arie Belldegrun: United States and IsraelBellco Legacy LLC: DelawareBellco Legacy IV LLC: DelawareVida Ventures LLC: NevadaVida Ventures III, L.P.: NevadaVida Ventures III-A, L.P.: Nevada

(d)

Title of class of securities:

Common Stock

(e)

CUSIP No.:

019770106

Item 4.

Ownership

(a)

Amount beneficially owned:

Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.Row 9 of Dr. Belldegrun's cover page includes 3,118,104 shares of common stock issuable within 60 days of December 31, 2024 upon the exercise of stock options held by the Reporting Person and 70,658 shares issuable upon the settlement of Restricted Stock Units held by the Reporting Person that are releasable within 60 days of December 31, 2024 and also includes (a) 4,710,120 shares of common stock beneficially owned by Bellco Legacy IV LLC, a limited liability company managed by Dr. Belldegrun and Rebecka Belldegrun, (b) 539,867 shares of common stock beneficially owned by Bellco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldegrun and Rebecka Belldegrun, (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), a limited liability company of which VV Manager LLC is the manager, of which Dr. Belldegrun is a Senior Managing Director, (d) 1,720,172 shares of common stock beneficially owned by Vida Ventures III, L.P. (Vida III), a limited partnership of which Vida Ventures GP III, LLC (Vida GP III) is the manager, of which Dr. Belldegrun is a Senior Managing Director, and (e) 3,965 shares of common stock beneficially owned by Vida Ventures III-A, L.P. (Vida III-A), a limited partnership of which Vida GP III is the manager, of which Dr. Belldegrun is a Senior Managing Director. Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida, Vida III and Vida III-A, except to the extent of any pecuniary interest therein, and other than for the purpose of determining his obligations under Section 13(d) of the Exchange Act.

(b)

Percent of class:

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage iscalculated based on 209,672,091 shares of common stock outstanding as of November 1, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 7, 2024. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Arie Belldegrun, M.D.

Signature:	/s/ Arie Belldegrun
Name/Title:	Arie Belldegrun, M.D.
Date:	02/13/2025

Bellco Legacy LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By Arie Belldegrun, M.D., Manager
Date:	02/13/2025

Bellco Legacy IV LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By Arie Belldegrun, M.D., Manager
Date:	02/13/2025

Vida Ventures LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By VV Manager LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director,
Date:	02/13/2025

Vida Ventures III, L.P.

Signature:	/s/ Arie Belldegrun
Name/Title:	By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director,
Date:	02/13/2025

Vida Ventures III-A, L.P.

Signature:	/s/ Arie Belldegrun
Name/Title:	By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director,
Date:	02/13/2025

Exhibit Information

Joint Filing Agreement

primary_doc.xml

Sec Form 13G Filing - Arie Belldegrun, M.D. filing for Allogene Therapeutics, Inc. (ALLO) - 2025-02-13